Latest On Novan, Inc (NOVN):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-16 02:47 EST | News | Novan, Inc. (NOVN) Q1 2023 Earnings Call Transcript | N/A |  |
| 2023-05-15 13:07 EST | News | Novan GAAP EPS of -$0.54 misses by $0.22, revenue of $3.17M misses by $3.02M | N/A | |
| 2023-03-31 08:16 EST | News | Novan (NOVN) Q4 2022 Earnings Call Transcript | N/A | |
| 2023-03-31 08:16 EST | News | Novan rises 12% on full-year result beat | N/A | |
| 2023-03-30 08:08 EST | News | Novan GAAP EPS of -$1.42 beats by $0.10, revenue of $23.7M beats by $4.34M | N/A | |
About Novan, Inc (NOVN):
Novan, Inc., a clinical development-stage biotechnology company, provides nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company also develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-ris read more...k human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. The company was incorporated in 2006 and is headquartered in Morrisville, North Carolina.
General
- Name Novan, Inc
- Symbol NOVN
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 23
- Fiscal Year EndDecember
- IPO Date2016-09-21
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryPharmaceuticals
- Gic SubIndustryPharmaceuticals
- Web URLhttp://www.novan.com
Valuation
- Price/Sales (Trailing 12 Mt.) 33.94
- Price/Book (Most Recent Quarter) 85.6
- Enterprise Value Revenue 44.7
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$0.19
- Next Year EPS Estimate -$0.15
- Operating Margin -522%
- Return on Assets -42%
- Revenue 4.92 million
- Earnings Per Share -$0.96
- Revenue Per Share $0.05
- Gross Profit -3907000
- Quarterly Earnings Growth -22.5%
Highlights
- Market Capitalization 254.08 million
- EBITDA -24745000
- Analyst Target Price $2.75
- Book Value Per Share $0.02
Share Statistics
- Shares Outstanding 150.79 million
- Shares Float 142.42 million
- % Held by Insiders 894%
- % Held by Institutions 8.03%
- Shares Short 5.32 million
- Shares Short Prior Month 6.28 million
- Short Ratio 0.33
- Short % of Float 4%
- Short % of Shares Outstanding 4%
Technicals
- Beta -0.05
- 52 Week High $2.59
- 52 Week Low $0.33
- 50 Day Moving Average 1.66
- 200 Day Moving Average 0.89
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
Novan, Inc (NOVN) Dividend Calendar:
Novan, Inc (NOVN) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Novan, Inc (NOVN) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Novan, Inc (NOVN) Chart:
Novan, Inc (NOVN) News:
Below you will find a list of latest news for Novan, Inc (NOVN) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Novan, Inc (NOVN) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest NOVN Trades:
Novan, Inc (NOVN) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-11-04 | 8-K (Current report) | |
| 2020-10-30 | 8-K (Current report) | |
| 2020-10-30 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-10-14 | 8-K (Current report) | |
| 2020-09-25 | 3 (Initial statement of beneficial ownership of securities) | |
| 2020-09-25 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-24 | 8-K (Current report) | |
| 2020-09-14 | 8-K (Current report) | |
| 2020-08-19 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-14 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-07-31 | 8-K (Current report) | |
| 2020-07-30 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-30 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-30 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-30 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-30 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-28 | 8-K (Current report) | |
| 2020-07-23 | 424B5 (Prospectus [Rule 424(b)(5)]) | |
| 2020-07-22 | 8-K (Current report) | |
| 2020-07-16 | 8-K (Current report) | |
Novan, Inc (NOVN) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Novan, Inc (NOVN). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 894%
Institutional Ownership: 803%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-03-03 | JOHN W PALMOUR | Director | Buy | 200,000.00 | 493,568.00 | | ||
| 2020-03-03 | MACHELLE SANDERS | Director | Buy | 7,000.00 | 7,000.00 | | ||
| 2019-07-02 | Life Sciences Holdings Ltd Malin | 10% Share Holder | Sell | 6,287.00 | 2.75 | 17,289.25 | 2,598,485.00 | |
| 2019-07-01 | Life Sciences Holdings Ltd Malin | 10% Share Holder | Sell | 913.00 | 2.74 | 2,501.62 | 2,604,772.00 | |
| 2019-06-28 | Life Sciences Holdings Ltd Malin | 10% Share Holder | Sell | 17,800.00 | 2.69 | 47,882.00 | 2,605,685.00 | |
| 2019-05-29 | G. Kelly Martin | Chief Executive Officer | Buy | 1,500.00 | 1.97 | 2,955.00 | 45,000.00 | |
| 2019-05-28 | G. Kelly Martin | Chief Executive Officer | Buy | 3,500.00 | 2.15 | 7,525.00 | 43,500.00 | |
| 2019-05-24 | JOHN W PALMOUR | Director | Buy | 20,000.00 | 2.20 | 44,000.00 | 293,568.00 | |
| 2019-05-22 | ROBERT ALEXANDER INGRAM | Director | Buy | 50,000.00 | 2.21 | 110,500.00 | 169,777.00 | |
| 2019-05-21 | W Kent Geer | Director | Buy | 5,000.00 | 1.90 | 9,500.00 | 15,828.00 | |
| 2019-05-20 | PAULA B STAFFORD | President and COO | Buy | 80,000.00 | 1.92 | 153,600.00 | 80,693.00 | |
| 2019-05-17 | JOHN M. GAY | VP, Finance & Corp. Controller | Buy | 14,900.00 | 1.50 | 22,350.00 | 15,000.00 | |
| 2019-05-17 | G. Kelly Martin | Chief Executive Officer | Buy | 40,000.00 | 1.43 | 57,200.00 | 40,000.00 | |
| 2019-05-17 | G. Kelly Martin | Chief Executive Officer | Buy | 20,000.00 | 1.43 | 28,600.00 | 60,000.00 | |
| 2019-05-17 | ANDREW NOVAK | VP, Accounting and Bus Ops | Buy | 5,400.00 | 1.47 | 7,938.00 | 6,700.00 | |
| 2019-05-17 | PAULA B STAFFORD | President and COO | Buy | 693.00 | 1.49 | 1,032.57 | 693.00 | |
| 2018-09-28 | ROBERT ALEXANDER INGRAM | Director | Buy | 50,000.00 | 2.84 | 142,000.00 | 119,777.00 | |
| 2018-09-26 | G. Kelly Martin | Chief Executive Officer | Buy | 10,000.00 | 2.73 | 27,300.00 | 40,000.00 | |
| 2018-08-22 | JEFF N HUNTER | EVP & Chief Business Officer | Buy | 11,667.00 | 1.12 | 13,067.04 | 186,666.00 | |
| 2018-08-22 | JOHN W PALMOUR | Director | Buy | 20,000.00 | 2.66 | 53,200.00 | 273,568.00 | |